匹妥布替尼(一种高选择性非共价可逆BTK抑制剂)治疗复发/难治性滤泡性淋巴瘤:1/2期BRUIN研究
BRUIN多中心1/2期研究纳入48例复发/难治性滤泡性淋巴瘤患者,接受匹妥布替尼单药治疗,中位既往治疗线数为3线。总缓解率为52.1%(95%CI 37.2-66.7),中位缓解持续时间10.2个月,中位无进展生存期5.8个月,中位随访35.2个月时中位总生存期不可估计。匹妥布替尼耐受性良好,2例(4.2%)因不良事件停药,4例(8.3%)因不良事件减量。
要点
- 复发/难治性滤泡性淋巴瘤患者接受匹妥布替尼单药治疗,总缓解率为52.1%(95%CI 37.2-66.7)。
- 中位缓解持续时间10.2个月(95%CI 3.7-25.7),中位无进展生存期5.8个月(95%CI 3.8-8.1)。
- 2例(4.2%)因不良事件停药,其中1例治疗相关;4例(8.3%)因不良事件减量,均为治疗相关。
核心结论
- 匹妥布替尼在经重度治疗的复发/难治性滤泡性淋巴瘤患者中显示出有前景的疗效且耐受性良好,值得进一步研究。
研究设计与样本
- 多中心1/2期BRUIN研究,纳入48例复发/难治性滤泡性淋巴瘤患者,接受匹妥布替尼单药治疗;中位年龄64.5岁(范围37.0-85.0),中位既往治疗线数3线(范围1-12)。
主要发现
- 总缓解率为52.1%(95%CI 37.2-66.7),中位缓解持续时间为10.2个月(95%CI 3.7-25.7)。
- 中位无进展生存期为5.8个月(95%CI 3.8-8.1),中位总生存期不可估计,中位随访35.2个月(四分位距31.1-41.8)。
- 24个月估计缓解持续时间率为33.3%(95%CI 15.9-51.9),24个月估计无进展生存率为25.6%(95%CI 13.9-39.1),24个月估计总生存率为75.1%(95%CI 59.5-85.4)。
- 2例(4.2%)因不良事件停药,其中1例为治疗相关;4例(8.3%)因不良事件减量,均为治疗相关。
关键数值与推荐
- 疗效评估采用Lugano 2014标准由研究者评估总缓解率。
- 总缓解率为52.1%(95%CI 37.2-66.7),中位缓解持续时间10.2个月(95%CI 3.7-25.7),中位无进展生存期5.8个月(95%CI 3.8-8.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory (R/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariably experience relapse. While newer therapies such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T cell) therapy are available, patient access and eligibility remain challenging. Here, we report the safety and efficacy of pirtobrutinib, a noncovalent (reversible) BTKi monotherapy in a R/R FL cohort from the multicenter phase 1/2 BRUIN study. Key end points included investigator-assessed overall response rate (ORR) per Lugano 2014 criteria, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Among 48 patients with FL, the median age was 64.5 years (range, 37.0-85.0). Patients had received a median of 3 (range, 1-12) prior lines of therapy. The ORR with pirtobrutinib was 52.1% (95% confidence interval [CI], 37.2-66.7), and median DoR was 10.2 months (95% CI, 3.7-25.7). Median PFS was 5.8 months (95% CI, 3.8-8.1), and median OS was not estimable, with a median follow-up of 35.2 months (interquartile range, 31.1-41.8). The estimated DoR, PFS, and OS rates at 24 months were 33.3% (95% CI, 15.9-51.9), 25.6% (95% CI, 13.9-39.1), and 75.1% (95% CI, 59.5-85.4), respectively. Pirtobrutinib was well tolerated, with 2 patients (4.2%) discontinuing treatment due to adverse events (AEs; 1 treatment-related) and 4 patients (8.3%) having dose reductions due to AEs (all treatment related). Pirtobrutinib showed promising efficacy and was well tolerated in this cohort of patients with heavily pretreated R/R FL, warranting further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03740529.
引用
- Shah NN, Zinzani PL, Wang M, et al. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025. PMID: 40845254. doi:10.1182/bloodadvances.2024014975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。